AKTS Stock — Aktis Oncology Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The field of targeted radiopharmaceuticals is currently led by two marketed products that illustrated transformative survival outcomes and quality of life benefits can be conferred by delivering radioisotopes to solid tumors.

Source: 10-K FY2025 via SEC EDGAR

Share price

$15.82

Market cap

$879.9M

Cash

$517.3M

Enterprise value

$362.6M

Balance sheet

Cash	$517.3M
Debt	$0.0M
Net cash	$517.3M
Enterprise value	$362.6M
Basic shares	55.6M shares
Fully diluted shares	63.4M shares
Fully diluted market cap	$1,002.2M
Cash per share	$9.30
Quarterly burn	$20.6M
Cash runway	25.1 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

55.6M

Pre-funded warrants

0.0M

Options

7.7M

RSUs

0.0M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

63.4M

Cap table as of 2026-06-30.

Price history

Loading AKTS daily closes…

Loading price history…

Next catalyst

AKY-1189 · Est. Feb 14, 2027 · quarter midpoint · guided in 8 wks

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Feb 14, 2027 in 8 wks quarter midpoint	AKY-1189 NECTINIUM-2 Phase 1b, preliminary data · NCT07020117	Phase 1b	Not disclosed	Q1 2027
GUIDEDEst. Jul 2, 2027 in 8 wks guidance midpoint	AKY-2519 Phase 1b in mCRPC, preliminary data · NCT07581184	Phase 1b	mCRPC	2027
Jan 12 - Feb 23 in 14 mo	[225Ac]Ac-AKY-1189 (therapeutic)	Phase 1	Urothelial Carcinoma Bladder; Triple Negative Breast Cancer (TNBC); Hormone Receptor Positive Breast Adenocarcinoma	—
Jan 12 - Feb 23 in 14 mo	[225Ac]Ac-AKY-2519 (therapeutic)	Phase 1	Castration Resistant Metastatic Prostate Cancer; Prostate Cancer; mCRPC (Metastatic Castration-resistant Prostate Cancer)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

[225Ac]Ac-AKY-1189

Phase 1 · Active Modality: miniprotein radioconjugate (actinium-225)

Target Nectin-4

Indications

Locally advanced or metastatic urothelial cancer (UC) (Phase 1)
Nectin-4 expressing solid tumors (incl. breast, lung) (Phase 1)

Catalysts

— Q1 2027

Status note Lead program; IND cleared April 2025; multi-site Phase 1b in the U.S. ongoing. Eli Lilly collaboration covers generation of anticancer radiopharmaceuticals on the miniprotein platform, not this asset specifically.

[225Ac]Ac-AKY-2519

Preclinical · Active Modality: miniprotein radioconjugate (actinium-225)

Target B7-H3

Indications

B7-H3 expressing tumors (Preclinical)

Status note Advancing through IND-enabling studies into clinical trials; discovery/preclinical R&D spend line item.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	[225Ac]Ac-AKY-1189 (therapeutic)
Lead indication	Urothelial Carcinoma Bladder
Lead phase	Phase 1
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07020117	Phase 1	Recruiting	Sponsor	AKTS	—	Urothelial Carcinoma Bladder; Triple Negative Breast Cancer (TNBC); Hormone Receptor Positive Breast Adenocarcinoma	Q1 2027 Est. Feb 14, 2027 · quarter midpoint
NCT07581184	Phase 1	Recruiting	Sponsor	AKTS	—	Castration Resistant Metastatic Prostate Cancer; Prostate Cancer; mCRPC (Metastatic Castration-resistant Prostate Cancer)	2027 Est. Jul 2, 2027 · guidance midpoint

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Aktis Oncology, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
EcoR1 Capital	4,824,469	no change	7.71%	2026-08-14
RTW Investments	1,592,043	no change	0.44%	2026-08-14
RA Capital Management	1,314,405	-188,679	0.37%	2026-08-14
Baker Bros. Advisors	996,351	no change	0.16%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

AKTS — Aktis Oncology Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

AKTS — Aktis Oncology Inc.